Impact of Preoperative Physical Activity on Bladder Cancer Surgery Outcomes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effects of preoperative physical activity on patients undergoing radical cystectomy for muscle-invasive bladder cancer. It aims to determine whether increased physical fitness prior to surgery can reduce perioperative morbidity. Conducted at the University of Munich, the study will follow a prospective randomized design over three years, focusing on patients with urothelial carcinoma of the bladder. The primary endpoint is to assess the impact of physical activity on complications associated with the surgery.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Urothelial cell cancer of the bladder
* Treatment with radical cystectomy

Exclusion Criteria:

* Need for walking aid
* Depression
* cardiovascular, neuromuscular or orthopaedic deficites / disorders
* Time to surgery \< 3 Weeks

Where it's running

• Department of Urology, LMU Hospital
  Munich, Bavaria, Germany Recruiting

Study contacts

• Study coordinator: Yannic Volz, PD Dr. med.
• Email: yannic.volz@med.uni-muenchen.de
• Phone: +49 089 4400 75970

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BL-M07D1: T-bren vs standard platinum chemo for HER2-expressing metastatic urothelial cancer after anti-PD-(L)1 therapy

  This trial tests whether T-bren can help people with HER2-expressing metastatic urothelial cancer who progressed after anti-PD-(L)1 therapy, compared with standard platinum-based chemotherapy.

  Recruiting at 2 sites Phase 3 SystImmune Inc. · Macon, Georgia and 1 other locations · NCT07869836

• Intravesical UGN-501 for Recurrent NMIBC (Phase 1, dose-escalation)

  This study tests whether UGN-501 can be safely given into the bladder to treat adults with recurrent non-muscle invasive bladder cancer.

  Recruiting at 6 sites Phase 1 UroGen Pharma Ltd. · Queen Creek, Arizona and 14 other locations · NCT07725796

• Calcium electroporation for bladder tumors in adults who can’t have standard treatments

  This first‑in‑human study tests intravesical calcium electroporation to see if it is safe and whether it shows early signs of benefit in adults with bladder tumors who have few other options.

  Recruiting Phase 1 Zealand University Hospital · Roskilde · NCT07555769

• Nectin-4 targeted alpha radiotherapy [225Ac]Ac-AKY-1189 for advanced solid tumors

  This trial will try a Nectin‑4–targeted radioactive drug called [225Ac]Ac‑AKY‑1189 in adults with locally advanced or metastatic solid tumors, including certain bladder, breast, lung, and cervical cancers.

  Recruiting at 14 sites Phase 1 Aktis Oncology, Inc. · Duarte, California and 13 other locations · NCT07020117

• Combination treatment for advanced urothelial carcinoma

  This study is testing a new combination of a drug called AM80 with standard chemotherapy and immunotherapy to see if it helps people with advanced bladder cancer feel better and live longer.

  Recruiting Phase 2 Nagoya University · Nagoya, Aichi-ken · NCT06983210

• Comparing two treatments for advanced urothelial carcinoma

  This study is testing if a combination of two treatments can help people with advanced bladder cancer do better than using just one of the treatments alone.

  Recruiting at 2 sites Phase 2 Mabwell (Shanghai) Bioscience Co., Ltd. · Changsha, Hunan and 1 other locations · NCT06823427

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.